Available online Apr 29, 2020.
[ Original ] Volume 29, Issue 1, 2020, Pages 152-157
Background: The disparity between the overall survival of breast cancer between high-income countries (HICs) and low- and middle-income countries (LMICs) has been majorly attributed to the high rate of diagnosis of Early Stage Breast Cancer (ESBC) in HICs, with about three-quarters and one-fifth of the total breast cancer patients diagnosed with ESBC in HICs and LMICs respectively. The median 5-year survival rate of ESBC in HICs is 86% while it is about 72% in Sub-Saharan Africa.
Objectives: To determine stage-specific five-year survival outcomes in women treated for ESBC.
Methods: We conducted a longitudinal, cohort study to assess the treatment and outcome of ESBC in a Nigerian tertiary hospital. Patients diagnosed and treated for ESBC over 5 years were recruited and followed up for a minimum of 5 years after treatment. Clinicopathologic parameters, disease progression and known vital status, were retrieved. A 5% level of significance was used.
Results: 67(9.6%)patients of 694 new cases of breast cancer seen over the study duration was treated for ESBC, of whichsixty- three (63) were followed up over the specified follow-up period. The mean age was 43(10) years. Based on the American Joint Committee on Cancer staging, 9 patients were stage IA, 16 stage IB, 16 stage IIA and 26 stage IIB respectively. The overall 5-year survival was 77.8%.
Conclusion: The survival pattern of our cohort fairly compares with reports in HICs, despite the challenges faced in the multimodal treatment protocol received by our patients.
Subscribe to have full access to PDF format of all articles and get print copy of Nigerian Medical Journal.
Volume 29 | Issue 1
Page Nos. 152-157
Online since Jan 28, 2020